GeneTether Therapeutics Inc. (CSE: GTTX)

GeneTether Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 29, 2024	Dec 30, 2023	Dec 30, 2022	Dec 30, 2021	Dec 30, 2020	Dec 30, 2019
Selling, General & Admin	0.57	0.55	1.18	1.23	0.01	0.03
Research & Development	0.18	0.2	0.53	0.4	0.06	0.05
Operating Expenses	0.75	0.75	1.72	1.64	0.07	0.09
Operating Income	-0.75	-0.75	-1.72	-1.64	-0.07	-0.09
Interest Expense	-	-	-	-0	-0	-0
Interest & Investment Income	0.05	0.05	0	-	-	-
Currency Exchange Gain (Loss)	0.01	0.01	-0	-0	-	-
Pretax Income	-0.7	-0.69	-1.72	-1.64	-0.07	-0.09
Net Income	-0.7	-0.69	-1.72	-1.64	-0.07	-0.09
Net Income to Common	-0.7	-0.69	-1.72	-1.64	-0.07	-0.09
Shares Outstanding (Basic)	39	46	43	36	27	1
Shares Outstanding (Diluted)	39	46	43	36	27	1
Shares Change (YoY)	-10.68%	7.75%	20.45%	32.93%	3729.11%	43.40%
EPS (Basic)	-0.02	-0.01	-0.04	-0.05	-0.00	-0.12
EPS (Diluted)	-0.02	-0.01	-0.04	-0.05	-0.00	-0.12
Free Cash Flow	-0.39	-0.46	-1.18	-0.74	-0.07	-0.1
Free Cash Flow Per Share	-0.01	-0.01	-0.03	-0.02	-0.00	-0.14
EBIT	-0.75	-0.75	-1.72	-1.64	-0.07	-0.09

Source: S&P Capital IQ. Standard template. Financial Sources.